Literature DB >> 30712423

Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT-naïve patients.

Kirill V Lepik1, Natalia B Mikhailova1, Ivan S Moiseev1, Elena V Kondakova1, Luibov A Tsvetkova1, Yuri R Zalyalov1, Evgeniya S Borzenkova1, Elena V Babenko1, Vadim V Baykov1, Inna V Markova1, Boris V Afanasyev1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30712423     DOI： 10.1080/10428194.2019.1573368

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  7 in total

1.  Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.

Authors:  Anastasia Beynarovich; Kirill Lepik; Natalia Mikhailova; Evgenia Borzenkova; Nikita Volkov; Ivan Moiseev; Yuri Zalyalov; Elena Kondakova; Andrey Kozlov; Lilia Stelmakh; Olga Pirogova; Lyudmila Zubarovskaya; Alexander Kulagin; Boris Afanasyev
Journal:  Int J Hematol       Date:  2022-05-05       Impact factor: 2.319

2.  Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma.

Authors:  Liudmila V Fedorova; Kirill V Lepik; Nikita P Volkov; Polina V Kotselyabina; Evgenia S Borzenkova; Marina O Popova; Anastasia V Beynarovich; Vadim V Baykov; Andrey V Kozlov; Ivan S Moiseev; Natalia B Mikhailova; Alexander D Kulagin
Journal:  Int J Clin Oncol       Date:  2021-11-26       Impact factor: 3.850

Review 3.  Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.

Authors:  Huimin Ma; Xin Li; Meng Lin; Kebing Lv; Mingzhi Zhang; Xiaolong Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure.

Authors:  Kirill V Lepik; Natalia B Mikhailova; Elena V Kondakova; Yuri R Zalyalov; Liudmila V Fedorova; Luibov A Tsvetkova; Polina V Kotselyabina; Evgeniya S Borzenkova; Elena V Babenko; Marina O Popova; Elena I Darskaya; Vadim V Baykov; Ivan S Moiseev; Boris V Afanasyev
Journal:  Hemasphere       Date:  2020-06-08

5.  Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.

Authors:  Pier Luigi Zinzani; Radhakrishnan Ramchandren; Armando Santoro; Ewa Paszkiewicz-Kozik; Robin Gasiorowski; Nathalie A Johnson; Jose S R de Oliveira; Valeria Buccheri; Guilherme Fleury Perini; Michael Dickinson; Andrew McDonald; Muhit Özcan; Naohiro Sekiguchi; Ying Zhu; Monika Raut; Todd L Saretsky; Akash Nahar; John Kuruvilla
Journal:  Blood Adv       Date:  2022-01-25

Review 6.  Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.

Authors:  Elham Roshandel; Farzaneh Tavakoli; Sayeh Parkhideh; Sedigheh Sadat Akhlaghi; Maria Tavakoli Ardakani; Masoud Soleimani
Journal:  Health Sci Rep       Date:  2022-03-08

Review 7.  Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.

Authors:  Amy Junghyun Lee; Kyung Won Kim; Young Chul Cho; Yousun Ko; Yu Sub Sung; Youngbin Shin; Jiwoo Lee; Mi-Hyun Kim
Journal:  J Clin Med       Date:  2021-05-23       Impact factor: 4.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.